DENV4 NS1 Antibody Patent US12606611B2 Granted to US Dept Health
Summary
The USPTO granted Patent No. US12606611B2 to the United States of America, as represented by the Secretary of the Department of Health & Human Services, covering antibodies that specifically bind to Dengue virus serotype 4 (DENV4) non-structural protein 1 (NS1). The patent includes 16 claims and names Elizabeth Anne Hunsperger and Tesfaye Gelanew Taye as inventors.
What changed
The USPTO issued Patent No. US12606611B2, a granted patent for antibodies specifically binding to DENV4 NS1, assigned to the Department of Health & Human Services. The patent application (No. 17583936) was filed on January 25, 2022, and the grant took effect on April 21, 2026.
Biopharmaceutical firms and researchers developing dengue diagnostic or therapeutic products should review this patent to assess potential freedom-to-operate implications. The patent claims six CDR amino acid sequences and methods for diagnosing DENV and treating DENV infections using the disclosed antibodies.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Antibodies which specifically bind to dengue virus serotype 4 (DENV4) non-structural protein 1 (NS1) and methods of use thereof to detect a DENV4 infection
Grant US12606611B2 Kind: B2 Apr 21, 2026
Assignee
The United States of America, as represented by the Secretary, Department of Health & Human Services
Inventors
Elizabeth Anne Hunsperger, Tesfaye Gelanew Taye
Abstract
The present disclosure relates to polypeptides that specifically bind to Dengue virus non-structural protein 1, including antibodies and fragments thereof. The antibody or antigen-binding fragment thereof may specifically bind Dengue virus (DENV) serotype 4 and include: a heavy chain variable region that comprises at least one CDR amino acid sequence selected from the group consisting of: SGYNWH, YIHYSGGTNYNPSLKS, RTGTVPFAY, SYVMH, YLNPYNDDTKYNEKFKG, and GPPYALDY. The present disclosure further relates to methods of producing the polypeptides of the present disclosure, methods of diagnosing DENV, and methods of treating a DENV infection.
CPC Classifications
C07K 16/1081 C07K 16/10 G01N 33/56983 G01N 2333/185 G01N 2800/26 G01N 2469/10
Filing Date
2022-01-25
Application No.
17583936
Claims
16
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.